Sequencing therapies for metastatic renal cell carcinoma
MetadataShow full item record
CitationDizman, N., Arslan, Z. E., Feng, M. ve Pal, S. K. (2020). Sequencing therapies for metastatic renal cell carcinoma. Urologic Clinics of North America, 47(3), 305-318. https://dx.doi.org/10.1016/j.ucl.2020.04.008
In an era of several therapeutic options available, optimal treatment sequencing is crucial to providing patients the most effective therapy and promoting quality of life. In clear cell renal cell carcinoma, a combination approach with an immunotherapy backbone, such as nivolumab/ipilimumab or axitinib/pembrolizumab, has a key role in the first-line setting. Safety and activity data support the transition to single-agent targeted therapies in the second-line setting. Nivolumab monotherapy possesses clinical and mechanistic rationale as a second-line therapeutic option for patients treated with targeted therapies in the first-line setting. Gene expression models are being generated from large prospective clinical trial data sets.